These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35091680)

  • 21. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Nassereddine S; Lap CJ; Haroun F; Tabbara I
    Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
    Middeke JM; Metzeler KH; Röllig C; Krämer M; Eckardt JN; Stasik S; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Brümmendorf TH; Naumann R; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Görlich D; Sauerland C; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Kaufmann M; Kunadt D; Wörmann B; Sockel K; von Bonin M; Herold T; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Baldus CD; Ehninger G; Schetelig J; Hiddemann W; Bornhäuser M; Stölzel F; Thiede C
    Blood Adv; 2022 Mar; 6(5):1394-1405. PubMed ID: 34794176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Srinivasan A; Zhou Y; Scordino T; Prabhu S; Wierenga A; Simon G; Wierenga KJ; Thompson J; Shah R; Sinha AA
    Pediatr Hematol Oncol; 2020 Aug; 37(5):431-437. PubMed ID: 32166993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
    Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
    Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
    Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
    J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
    Yoshimi A; Lin KT; Wiseman DH; Rahman MA; Pastore A; Wang B; Lee SC; Micol JB; Zhang XJ; de Botton S; Penard-Lacronique V; Stein EM; Cho H; Miles RE; Inoue D; Albrecht TR; Somervaille TCP; Batta K; Amaral F; Simeoni F; Wilks DP; Cargo C; Intlekofer AM; Levine RL; Dvinge H; Bradley RK; Wagner EJ; Krainer AR; Abdel-Wahab O
    Nature; 2019 Oct; 574(7777):273-277. PubMed ID: 31578525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
    Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M
    Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
    Issa GC; DiNardo CD
    Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
    Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
    Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
    Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
    J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.
    Stein EM
    Clin Cancer Res; 2016 Jan; 22(1):16-9. PubMed ID: 26553750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mir142 loss unlocks IDH2
    Marshall A; Kasturiarachchi J; Datta P; Guo Y; Deltcheva E; James C; Brown J; May G; Anandagoda N; Jackson I; Howard JK; Ghazaly E; Brooks S; Khwaja A; Araki M; Araki K; Linch D; Lord GM; Enver T; Nimmo R
    Sci Rep; 2020 Nov; 10(1):19390. PubMed ID: 33173219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.